# INSM1

## Overview
INSM1, or Insulinoma-associated 1, is a gene that encodes the INSM transcriptional repressor 1, a zinc-finger transcription factor involved in neuroendocrine differentiation and development. The INSM1 protein is characterized by its zinc-finger motifs, which facilitate its role as a transcriptional repressor by binding to specific DNA sequences and regulating gene expression. It plays a crucial role in the differentiation of neuroendocrine cells, including those in the pancreas and adrenal glands, by modulating the expression of key developmental genes. The protein's structure includes a proline-rich amino-terminal domain and a carboxyl-terminal sequence with five C2H2-type zinc-finger motifs, which are essential for its DNA-binding and repressive functions (Zhu2017Solution; Lan2009Structure). INSM1 is transiently expressed during embryonic development and is implicated in various neuroendocrine tumors, making it a potential target for cancer therapy (Chen2015INSM1; Lan2009Structure).

## Structure
The INSM1 protein is a transcriptional repressor involved in neuroendocrine differentiation, characterized by its zinc-finger motifs. The protein consists of 510 amino acids and can be divided into two major domains: the amino-terminal domain (aa 1-250) and the carboxyl-terminal sequence (aa 251-510) (Lan2009Structure). The amino-terminal domain is rich in proline, glycine, and alanine residues, featuring proline-rich sequences that serve as protein-protein interacting domains. It also includes a Snail/Ggi-1 (SNAG) motif (Zhu2017Solution).

The carboxyl-terminal sequence contains five C2H2-type zinc-finger motifs, which are symmetrically spaced and suggest a precise mode of DNA binding. Notably, the first zinc-finger sequence lacks the last His residue, replaced by Arg. Zinc-fingers 2 and 3 are critical for target gene binding (Lan2009Structure). The structure of zinc fingers 4 and 5 (ZF4-5) has been elucidated using NMR, revealing a canonical ββα fold with a head-to-tail arrangement. These zinc fingers bind weakly to DNA, indicating a non-canonical role in DNA interaction (Zhu2017Solution).

The protein's molecular mass is approximately 52,923 Da, with a predicted isoelectric point (pI) of 9.1 (Lan2009Structure). The zinc-finger motifs are highly conserved across species, underscoring their importance in the protein's function as a transcription factor (Lan2009Structure).

## Function
INSM1 (INSM transcriptional repressor 1) is a zinc-finger transcription factor that plays a critical role in neuroendocrine differentiation and development. It functions primarily as a transcriptional repressor, regulating gene expression by binding to specific DNA sequences. INSM1 is involved in the repression of the neuroD/β2 gene through the recruitment of cyclin D1 and histone deacetylases (HDACs), particularly HDAC-1 and HDAC-3, which modify chromatin structure to suppress transcription (Liu2006INSM1).

In the developing pancreas, INSM1 acts as a transcriptional repressor by binding to the promoters of target genes such as NeuroD/β2 and insulin, suppressing their expression. This repression is crucial for the differentiation of pancreatic endocrine cells, as evidenced by impaired β-cell development in INSM1 knockout mice (Lan2009Structure). INSM1 also plays a role in the differentiation of chromaffin cells in the sympathetic adrenal lineage, essential for catecholamine synthesis (Lan2009Structure).

INSM1 is transiently expressed during embryonic development in various tissues, including the nervous system and endocrine organs, where it coordinates cell cycle exit and differentiation (Mahalakshmi2020Insulinomaassociated; Lan2009Structure). Its expression is significantly reduced after birth, except in certain neurogenic regions where it continues to influence neurogenesis (Lan2009Structure).

## Clinical Significance
Alterations in the expression of the INSM1 gene are associated with several neuroendocrine tumors, including neuroblastoma, medulloblastoma, retinoblastoma, small cell lung cancer (SCLC), and medullary thyroid carcinoma. In neuroblastoma, INSM1 is involved in a positive-feedback loop with N-myc, enhancing cell viability and oncogenesis. Overexpression of INSM1 in neuroblastoma is linked to increased cell proliferation, invasion, and poor clinical outcomes, including shorter disease-free survival and higher recurrence rates (Chen2015INSM1; Metovic2022Overexpression).

In medulloblastoma, INSM1 expression is regulated by the Sonic Hedgehog (Shh) signaling pathway, and its overexpression is observed in tumors with activated Hedgehog signaling (De2008An). In SCLC, INSM1 is upregulated and interacts with neuroendocrine genes like ASCL1, promoting tumor growth through complex transcriptional networks (Rocha2022InsulinomaAssociated).

INSM1 is also a marker for neuroendocrine differentiation in various tumors, and its expression pattern suggests a dedifferentiation event that mimics embryonic development (Lan2009Structure). The gene's role in these tumors highlights its potential as a target for cancer gene therapy (Rocha2022InsulinomaAssociated; Lan2009Structure).

## Interactions
INSM1 (INSM transcriptional repressor 1) is involved in several key interactions with proteins and nucleic acids that are crucial for its function as a transcriptional repressor. It interacts with cyclin D1, a cell cycle regulator, enhancing its repressive activity on the neuroD/β2 gene promoter. This interaction is mediated through the recruitment of histone deacetylases (HDAC-1 and HDAC-3), which modify chromatin structure to suppress gene expression (Liu2006INSM1). INSM1 also binds to the neuroD/β2 promoter sequence, with cyclin D1 enhancing this binding, leading to significant suppression of promoter activity (Liu2006INSM1).

INSM1 interacts with RACK1, an adaptor protein, which is essential for enhancing insulin receptor-mediated signaling. This interaction involves the proline-rich region in the N-terminus of INSM1 and affects the phosphorylation of AKT, a key component of the PI3K/AKT pathway (Zhang2014Extranuclear). The interaction with RACK1 also influences the expression of the Nkx6.1 gene, which is linked to INSM1's extra-nuclear activity (Zhang2014Extranuclear).

The SNAG domain of INSM1 is crucial for recruiting histone-modifying factors such as Kdm1a, Hdac1/2, and Rcor1-3, which are necessary for the differentiation of pituitary endocrine cells (Welcker2013Insm1).


## References


[1. (Liu2006INSM1) Wei-Dong Liu, Hong-Wei Wang, Michelle Muguira, Mary B. Breslin, and Michael S. Lan. Insm1 functions as a transcriptional repressor of the neurod/β2 gene through the recruitment of cyclin d1 and histone deacetylases. Biochemical Journal, 397(1):169–177, June 2006. URL: http://dx.doi.org/10.1042/bj20051669, doi:10.1042/bj20051669. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20051669)

[2. (Rocha2022InsulinomaAssociated) Renato Rocha and Rui Henrique. Insulinoma-associated protein 1 (insm1): diagnostic, prognostic, and therapeutic use in small cell lung cancer. Journal of Molecular Pathology, 3(3):140–167, August 2022. URL: http://dx.doi.org/10.3390/jmp3030013, doi:10.3390/jmp3030013. This article has 2 citations.](https://doi.org/10.3390/jmp3030013)

[3. (Chen2015INSM1) Chiachen Chen, Mary B. Breslin, and Michael S. Lan. Insm1 increases n-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget, 6(34):36700–36712, October 2015. URL: http://dx.doi.org/10.18632/oncotarget.5485, doi:10.18632/oncotarget.5485. This article has 16 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.5485)

[4. (Lan2009Structure) Michael S. Lan and Mary B. Breslin. Structure, expression, and biological function of insm1 transcription factor in neuroendocrine differentiation. The FASEB Journal, 23(7):2024–2033, February 2009. URL: http://dx.doi.org/10.1096/fj.08-125971, doi:10.1096/fj.08-125971. This article has 113 citations.](https://doi.org/10.1096/fj.08-125971)

[5. (Metovic2022Overexpression) Jasna Metovic, Francesca Napoli, Simona Osella-Abate, Luca Bertero, Cristian Tampieri, Giulia Orlando, Maurizio Bianchi, Diana Carli, Franca Fagioli, Marco Volante, and Mauro Papotti. Overexpression of insm1, notch1, neurod1, and yap1 genes is associated with adverse clinical outcome in pediatric neuroblastoma. Virchows Archiv, 481(6):925–933, September 2022. URL: http://dx.doi.org/10.1007/s00428-022-03406-4, doi:10.1007/s00428-022-03406-4. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00428-022-03406-4)

[6. (Zhu2017Solution) Jiang Zhu, Huapu Wang, Theresa A. Ramelot, Michael A. Kennedy, Rui Hu, Xiali Yue, Maili Liu, and Yunhuang Yang. Solution nmr structure of zinc finger 4 and 5 from human insm1, an essential regulator of neuroendocrine differentiation: solution nmr structure of human insm1 zf4-5. Proteins: Structure, Function, and Bioinformatics, 85(5):957–962, February 2017. URL: http://dx.doi.org/10.1002/prot.25259, doi:10.1002/prot.25259. This article has 4 citations.](https://doi.org/10.1002/prot.25259)

[7. (Welcker2013Insm1) Jochen E. Welcker, Luis R. Hernandez-Miranda, Florian E. Paul, Shiqi Jia, Andranik Ivanov, Matthias Selbach, and Carmen Birchmeier. Insm1 controls development of pituitary endocrine cells and requires a snag domain for function and for recruitment of histone-modifying factors. Development, 140(24):4947–4958, December 2013. URL: http://dx.doi.org/10.1242/dev.097642, doi:10.1242/dev.097642. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.097642)

[8. (Zhang2014Extranuclear) Tao Zhang, Chiachen Chen, Mary B. Breslin, Kejing Song, and Michael S. Lan. Extra-nuclear activity of insm1 transcription factor enhances insulin receptor signaling pathway and nkx6.1 expression through rack1 interaction. Cellular Signalling, 26(4):740–747, April 2014. URL: http://dx.doi.org/10.1016/j.cellsig.2013.12.014, doi:10.1016/j.cellsig.2013.12.014. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2013.12.014)

[9. (Mahalakshmi2020Insulinomaassociated) B. Mahalakshmi, Rathinasamy Baskaran, M. Shanmugavadivu, Ngoc Tuan Nguyen, and Bharath Kumar Velmurugan. Insulinoma-associated protein 1 (insm1): a potential biomarker and therapeutic target for neuroendocrine tumors. Cellular Oncology, 43(3):367–376, March 2020. URL: http://dx.doi.org/10.1007/s13402-020-00505-9, doi:10.1007/s13402-020-00505-9. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13402-020-00505-9)

[10. (De2008An) Enrico De Smaele, Caterina Fragomeli, Elisabetta Ferretti, Marianna Pelloni, Agnese Po, Gianluca Canettieri, Sonia Coni, Lucia Di Marcotullio, Azzura Greco, Marta Moretti, Concezio Di Rocco, Simona Pazzaglia, Marella Maroder, Isabella Screpanti, Giuseppe Giannini, and Alberto Gulino. An integrated approach identifies nhlh1 and insm1 as sonic hedgehog-regulated genes in developing cerebellum and medulloblastoma. Neoplasia, 10(1):89-IN36, January 2008. URL: http://dx.doi.org/10.1593/NEO.07891, doi:10.1593/neo.07891. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1593/NEO.07891)